Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer

LONDON–(BUSINESS WIRE)– #GSK–Jemperli (dostarlimab-gxly) plus chemo approved in US as new frontline treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Recent Articles